Background
==========

In recent decades, the continuing accumulation of knowledge and the increasing number of reports providing evidence regarding the beneficial health effects of polyunsaturated fatty acids (PUFA) have attracted the attention of the medical and public community. Consumers are becoming increasingly aware of the relationships between diet and health and also of the importance of the diet for general physical and mental wellbeing \[[@B1],[@B2]\]. Many clinical and epidemiologic studies have indicated a positive impact of long-chain omega-3 fatty acids (n-3 long-chain polyunsaturated fatty acids, n-3 LC-PUFA) on human health and disease. Beneficial effects of n-3 LC-PUFA are described in infant development, cancer, and cardiovascular diseases (e.g., \[[@B3]-[@B6]\]), lipid and glucose metabolism (e.g., \[[@B7]-[@B10]\]), inflammation (e.g., \[[@B11],[@B12]\]), and more recently, in various mental illnesses including depression, attention-deficit hyperactivity disorder, and dementia (e.g.,\[[@B13]\]). It has been demonstrated that diets containing higher levels of n-3 LC-PUFA \[namely DHA (docosahexaenoic acid; C22:6n-3) and EPA (eicosapentaenoic acid; C20:5n-3)\], may reduce cardiovascular risk in diabetes by inhibiting platelet aggregation, improving lipid profiles, and reducing cardiovascular mortality. Thus, n-3 LC-PUFA were particularly recommended to people with diabetes and metabolic disorders associated to obesity \[[@B5],[@B14]\]. Their beneficial health effects may be mediated through multiple distinct mechanisms, including alterations in cell membrane composition and function, gene expression, or eicosanoid biosynthesis \[[@B15],[@B16]\]. It is known that n-3 LC-PUFA can exert important metabolic effects due to their ability to modulate the transcription of regulatory genes with function in lipid metabolism \[[@B17]-[@B21]\].

The n-3 LC-PUFA, like DHA and EPA, are particularly abundant in oily cold-water fish and seafood, however, they are also present in other animal products (e.g., ruminant meat and milk) but in lower concentrations. Increases of n-3 LC-PUFA content in the human diet can be achieved by dietary supplementation, but there is also a potential to alter the natural fatty acid (FA) profile in food from animals. FA composition of meat and milk reflects both, FA biosynthesis in the respective animal tissue and FA composition of ingested nutrients. A recent study showed that cattle and lambs fed grass-diet in the period before slaughter had an increased content of beneficial FAs in meat, and that subsequent moderate consumption of the respective meat had resulted in increased plasma and platelet n-3 LC-PUFA concentrations in healthy human individuals \[[@B22]\]. A ruminant diet on grass, which is rich in α-linolenic acid (C18:3n-3, ALA) compared to cereal-based concentrate diet can influence the FA profile of meat in the desired direction and improve its nutritional value \[[@B23]-[@B25]\]. However, the link between nutritional intake of FAs and its subsequent concentration in skeletal muscle is stronger in monogastric animals (pigs, poultry) than in ruminants due to hydrogenation of dietary FAs in the rumen (e.g., \[[@B26]\]).

In addition to the environmental conditions, genetic factors may also have a substantial effect on the variability of FA composition in animal products, especially for ruminants \[[@B27]\]. Consequently, genetic selection and breeding of animals with favorably enriched n-3 LC-PUFA content in skeletal muscle can provide a rich source of the desired beneficial FAs for the human diet. Therefore, it is necessary to elucidate the molecular-genetic background of fatty acid composition in bovine skeletal muscle for identifying the genes or gene variants favorable for human nutrition.

Numerous quantitative trait loci (QTL) affecting meat quality traits in cattle like marbling and FA composition have been identified on a variety of bovine chromosomes (<http://www.animalgenome.org/cgi-bin/gbrowse/bovine/>), which enabled subsequent identification of positional candidate genes, which are located in the vicinity of identified QTL and have putative physiological functions regarding FA synthesis in skeletal muscle. These candidate genes for lipid-associated traits have been studied for their possible role regarding phenotypic variation observed between and within breeds. DNA variants in a variety of genes involved in lipid synthesis and FA metabolism have been found to influence FA composition in bovine muscle tissue and carcass (*SCD1*, \[[@B28]-[@B34]\], *SREBP-1*\[[@B29]\], *FASN*\[[@B29],[@B34]-[@B37]\], *FABP4*and *LXRα*\[[@B38]\], *GH*\[[@B29]\], *ACACA*\[[@B39]\], myostatin \[[@B40],[@B41]\], leptin \[[@B33]\]).

However, the biochemical processes and the molecular background affecting the genetic variability of the complex polygenic trait of FA composition are not yet completely understood, particularly with regard to European cattle breeds, because the majority of recent studies have been performed on the very specific genetic background of Japanese Black cattle.

Therefore, the aim of this study was to identify genetic factors affecting the variation of FA composition in bovine skeletal muscle. For our study, we took advantage of a unique F~2~resource population generated from the major European cattle breeds Charolais and German Holstein by means of embryo transfer and foster mothers \[[@B42]\]. In previous studies, this population had been shown to segregate for two major loci (*NCAPG*and *MSTN*) associated with prenatal and pubertal growth, postnatal body composition and general lipid deposition \[[@B43],[@B44]\].

Results and discussion
======================

The animals from our resource cross population were kept and fed at standardized uniform conditions and slaughtered at the same age. Therefore, we can exclude exogenous factors due to differences in herd, age, feeding and gender. Consequently, differences in skeletal muscle fatness or FA composition should be due to differences in endogenous factors of the animals like the genetic background. The primary focus of our study was to discover phenotypic differences of FA composition in skeletal muscle between the individual animals of the resource population due to genetic variation.

QTL analysis and identification of ACSL1 as a positional and functional candidate gene
--------------------------------------------------------------------------------------

An initial QTL analysis in the Charolais × German Holstein cross population identified a QTL for FA composition on bovine chromosome 27 (BTA27) as exemplified for n-3 LC-PUFA in Figure [1](#F1){ref-type="fig"}. In our study, the trait n-3 LC-PUFA represents n-3 PUFA exceeding a carbon chain length of C18. The QTL interval corresponded to a region, where previously QTL affecting marbling had been detected in a Bos indicus × Bos taurus cross and two commercial US Angus populations \[[@B45],[@B46]\]. The QTL explained 20.5% variance in the model calculated as the relative reduction of the residual variance due to including the QTL in the model \[[@B47]\].

![**QTL for the relative content of n-3 long chain PUFA (n-3 LC PUFA) on BTA27**. Solid boxes: *ACSL1*c.481-233A\>G effect not included in the model, open boxes: *ACSL1*c.481-233A\>G included in the model as a fixed effect. LRT significance threshold is indicated by a dashed line (α = 0.05: 7.23).](1471-2156-12-96-1){#F1}

Furthermore, QTL for FA composition, myristic acid, (C14:0) and oleic acid (C18:1) content, have been reported in this chromosomal region in a Jersey × Limousin back-cross cattle population \[[@B48]\]. In our study, the QTL interval affecting FA composition in skeletal muscle displayed a peak between 15 and 16 cM on our genetic map of BTA27 corresponding to a genomic position at approximately 16 Mb on the current bovine genome assembly of the chromosome (NCBI mapviewer, build 5.2, [http://www.ncbi.nlm.nih.gov/projects/mapview/map_search.cgi?taxid = 9913](http://www.ncbi.nlm.nih.gov/projects/mapview/map_search.cgi?taxid=9913)).

Based on its chromosomal position and integration in biochemical pathways of lipid metabolism, we identified the *acyl-CoA synthetase long-chain family member 1*(*ACSL1*) gene as the most plausible positional and functional candidate gene underlying the QTL with effect on FA composition on BTA27. The *ACSL1*gene is located exactly under the peak of the QTL interval. Its protein, the ACSL1 enzyme, is known to catalyze the first step of activation of long-chain (LC) FAs by converting them into LC acyl CoA thioesters for channeling towards chain elongation, triacylglyceride synthesis or FA oxidation \[[@B49]\]. ACSL1 has a key function in both the synthesis of cellular lipids and FA degradation, and is also necessary for phospholipid remodeling \[[@B50]\]. Due to its physiological biochemical function, it can be suggested that ACSL1 plays an important role in lipid metabolism, insulin resistance and obesity. Recently, a study in humans reported that a gene variant located in intron 1 of the *ACSL1*gene can influence the metabolic syndrome risk (characterized by insulin resistance, dyslipidaemia, abdominal obesity and hypertension associated to type 2 diabetes), and that this *ACSL1*genotype-dependent effect can be modulated by dietary PUFA intake suggesting a gene-nutrient interaction \[[@B51]\].

Structure analysis and screening for polymorphisms of the ACSL1 gene
--------------------------------------------------------------------

Although sequences for the *ACSL1*gene and protein were deposited in the bovine genome databases, we found inconsistencies regarding the structural annotation of the gene in the bovine genome assemblies. A correct and conclusive structural gene annotation is a prerequisite for subsequent screening for gene variants and analysis of their functional relevance. Therefore, the first step of our study focused on the experimental confirmation of the structure of the *ACSL1*gene on the genomic and cDNA level. Experimental verification by RT-PCR, re-sequencing and comparative sequence analyses confirmed the genomic annotation of the bovine *ACSL1*gene in the alternate UMD_3.1 genome assembly (Figure [2](#F2){ref-type="fig"}), which is in contrast to the reference genome assembly Btau4.2 ([http://www.ncbi.nlm.nih.gov/projects/mapview/map_search.cgi?taxid = 9913](http://www.ncbi.nlm.nih.gov/projects/mapview/map_search.cgi?taxid=9913)).

![**Structure of the bovine *ACSL1*gene and detection of polymorphic sites**. Reference mRNA sequence: NM_001076085.1. SNPs included in the association analysis are bold framed.](1471-2156-12-96-2){#F2}

Re-sequencing of DNA from pools and individuals differing in IMF content and Δ^9^desaturase activity index included a total of 8.5 Kb of genomic DNA. Comparative sequence analysis revealed a total of 19 single nucleotide polymorphisms (SNPs) in the targeted gene regions (Table [1](#T1){ref-type="table"}). Three synonymous exonic (exons 6, 7 and 20), six intronic (introns 5, 6, 9, 13, 16 and 20), six SNPs in the promoter region and four SNPs in the 3\'UTR of the bovine *ACSL1*gene were detected (Figure [2](#F2){ref-type="fig"}, Table [1](#T1){ref-type="table"}). Eleven out of these SNPs identified in our study were novel and not previously represented in the SNP database (version 133) at NCBI.

###### 

Identified SNPs within the ACSL1 locus and positions on the bovine genome assemblies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP ID\                         Gene region   Variation relative to reference sequence   Position on NW_001494406.2 (Btau4.2)   Position on NW_003104605.1 (UMD_3.1)   Allele\              SNP accession number (dbSNP, NCBI ss\#)
  relative to coding sequence\*                                                                                                                                          frequency            
  ------------------------------- ------------- ------------------------------------------ -------------------------------------- -------------------------------------- -------------------- -----------------------------------------
  c.-569_570del AC                Promoter      Indel TG                                   1918795                                389858                                 Not analyzed         ss469271165

  c.-224_225del GG                Promoter      Indel (C)~5-7~                             1918451                                389615                                 Not analyzed         ss469271166

  c.-196G\>A                      Promoter      C\>T                                       1918422                                3894586                                Not analyzed         ss469271167

  c.-167G\>C                      Promoter      C\>G                                       1918393                                3894557                                Not analyzed         ss469271168

  c.-151G\>C                      Promoter      C\>G                                       1918377                                3894541                                Not analyzed         ss469271169

  **c.-122G\>A**                  Promoter      C\>T                                       1918348                                3894512                                0.67 (G)/0.33 (A)    ss469271170

  **c.481-233A\>G**               Intron 5      T\>C                                       1876389                                3852106                                0.73 (A)/0.27 (G)    ss469271171

  **c.516C\>G**                   Exon 6        G\>C                                       1876121                                3852284                                0.57 (C)/0.43 (G)    ss469271172

  **c.580+114C\>G**               Intron 6      G\>C                                       1875943                                3852552                                0.33 (C)/0.67 (G)    ss469271173

  **c.584A\>G**                   Exon 7        T\>C                                       1875838                                3852001                                0.07 (G)/0.94 (A)    ss469271174

  **c.845-58T\>G**                Intron 9      A\>C                                       1871919                                3848082                                0.75 (T)/0.21 (G)5   ss469271175

  **c.1267-100C\>T**              Intron 13     G\>A                                       1864210                                3840373                                0.24 (T)/0.76 (C)    ss469271176

  c.1525-131C\>T                  Intron 16     G\>A                                       1859370                                3835533                                Not analyzed         ss469271177

  **c.1938T\>G**                  Exon 20       A\>C                                       Not annotated                          3831586                                0.75 (T)/0.25 (G)    ss469271178

  **c.1959+56G\>A**               Intron 20     C\>T                                       Not annotated                          3831509                                0.24 (A)/0.76 (G)    ss469271179

  c.2099+1023del A                3\'UTR        Indel A                                    1853870                                3829944                                Not analyzed         ss469271180

  c.2099+1030 C\>A                3\'UTR        C\>A                                       1853863                                3829937                                Not analyzed         ss469271181

  c.2099+1032 A\>C                3\'UTR        A\>C                                       1853861                                3829935                                Not analyzed         ss469271182

  c.2099+1034 C\>A                3\'UTR        C\>A                                       1853859                                3829933                                Not analyzed         ss469271183
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*SNP nomenclature according to the translation start codon ATG, reference sequence NM_001076085.1. SNPs marked in bold were included in the association analysis. Genomic positions of the SNPs were inferred from the current versions of the refererence and alternative bovine genome assemblies Btau4.2 and UMD_3.1 available at NCBI (<http://www.ncbi.nlm.nih.gov/genome/guide/cow/index.html>).

Association of ACSL1 gene variants with PUFA profile in skeletal muscle
-----------------------------------------------------------------------

The association analysis included all exonic and intronic *ACSL1*gene variants (except for the one in intron 16) and one SNP in the promoter region, which were identified by re-sequencing and validated by genotyping in the Charolais × German Holstein resource population. The nine SNPs analyzed in the Holstein × Charolais cross bred population showed a minor allele frequency ≥ 0.2 in the analyzed data set (Table [1](#T1){ref-type="table"}). Intragenic linkage disequilibrium (LD) analysis revealed a strong LD between the SNPs in intron 20, exon 20, intron 13 and intron 9 (r^2^\>0.9), whereas there was only a moderate LD (0.5 \< r^2^\<0.6) between these SNPs and the one in intron 5.

The association analysis with intragenic *ACSL1*SNPs revealed that the SNP located in intron 5 of the *ACSL1*gene (*c.481-233A\>G*) showed the most significant associations with FA composition in skeletal muscle. The gene variant *ACSL1 c.481-233A\>G*was significantly associated with the relative content of distinct fractions of unsaturated FAs, n-3 FA, PUFA, n-3 LC-PUFA and docosapentaenoic fatty acid (DPA) as well as with the absolute content of total FA, MUFA, and trans vaccenic acid (C18:1trans-11) in *M. longissimus dorsi*(Table [2](#T2){ref-type="table"}). The results revealed that the *c.481-233A*allele of this gene variant is strongly associated with a higher relative level of n-3 FA, PUFA, DPA, and n-3 LC-PUFA. In contrast, the c.481-233A allele showed a decreasing effect on content of C18:1trans-11, total FA, and MUFA, and tended to be associated with a lower IMF content in skeletal muscle compared to the *c.481-233G*allele. The *c.481-233A*allele had a higher freqeuncy (73%) in the analyzed population compared to the alternative allele (27%).

###### 

Association of the SNP in intron 5 of the *ACSL1*gene (*c.481-233A\>G*) with variation in intramuscular fatty acid composition and fat content

                                  Model without IMF as covariate   Model with IMF as covariate                                                                               
  ------------------------------- -------------------------------- ----------------------------- ------- ------ ------- ------ ------ ----- ----------- ------ ------ ------ ------
  Total FA \[mg\]**\***^&^        6.2                              0.0130                        3.70    0.07   3.88    0.07          3.8   0.0507                           
  MUFA \[mg\]**\***^&^            5.9                              0.0154                        3.29    0.08   3.48    0.09          2.9   0.0874                           
  n-3 FA \[%\]**\***^\#^          9.7                              0.0018^a^                     0.16    0.05   0.01    0.06   11.4   5.8   0.0159      0.42   0.04   0.36   0.04
  PUFA \[%\]**\***^\#^            7.1                              0.0079^b^                     1.12    0.05   0.98    0.06   3.5    3.9   0.0477                           
  n-3 LC PUFA \[%\]^\#^           6.7                              0.0099^b^                     0.24    0.03   0.16    0.04   3.4    3.5   0.0628                           
  C18:1trans-11 \[mg\]**\***^&^   10.5                             0.0012^a^                     1.31    0.10   1.63    0.12   6.5    8.1   0.0045^a^   0.86   0.09   1.07   0.10
  C22:5n-3 \[%\]^\#^              7.2                              0.0071 ^b^                    0.16    0.02   0.11    0.03   3.6    5.9   0.0150      0.27   0.02   0.23   0.02
  PUFA/SFA**\***                  7.3                              0.0069^b^                     -0.79   0.06   -0.94   0.07   3.6    4.2   0.0407                           
  P/S**\***                       6.7                              0.0099^b^                     -1.02   0.05   -1.15   0.06   3.2    3.2   0.0758                           
  LA/ALA**\***                    4.9                              0.0265                        1.03    0.03   0.97    0.03          1.9   0.1720                           
  IMF \[%\]                       3.1                              0.0776                        1.11    0.18   1.42    0.21   1.7                                           

\*Trait data log-transformed, ^&^absolute content of fatty acids (mg/100 g of skeletal muscle), ^\#^relative content of fatty acids (percentage of the respective fatty acid fraction relative to total fatty acid amount)

LTR: likelihood ratio test, p: significancy of allelic effects, Var: variance explained, SE: standard error, ^a^q-value \<0.05, ^b^q-value \<0.1, \*\*% variance in the model calculated as the relative reduction of the residual variance due to including the SNP in the model \[[@B47]\].

Allelic effects of the *ACSL1*SNP (c.481-233A\>G) on different FA fractions: n-3 fatty acids (n-3 FA = C18:3n-3 + C18:4n-3 + C20:5n-3 + C22:5n-3 + C22:6n-3), poly-unsaturated fatty acids (PUFA = n-3 FA + n-6 FA \[C18:2n-6 + C18:3n-6 + C20:2n-6 + C20:3n-6 + C20:4n-6 + C22:2n-6 + C22:4n-6\]), n-3 long-chain PUFA (n-3 LC-PUFA = C20:3n-3 + C22:6n-3 + C22:5n-3 + C20:5n-3), total FA, mono-unsaturated fatty acids (MUFA), docosapentaenoic fatty acid (DPA, C22:5n-3), trans vaccenic acid (TVA, C18:1trans-11) and the ratios: PUFA/SFA (saturated fatty acids = C12:0 + C14:0 + C16:0 + C17:0 + C18:0 + C20:0 + C24:0), P/S (C18:2 n-6 + C18:3 n-3/C14:0 + C16:0 + C18:0), LA/ALA (C18:2 n-6/C18:3 n-3), and the intramuscular fat content (IMF).

Although the *c.481-233A*allele tends to be associated with a slightly lower total IMF content, the relative content of the FA fractions, n-3 FA, PUFA, DPA, and n-3 LC-PUFA, known to exert health-beneficial effects in humans is highly increased indicating a higher nutritional value for beef originating from animals with the favorable *ACSL1*allele.

The strongest allelic effect of the *ACSL1 c.481-233A\>G*locus was observed for n-3 FA content. This trait also includes the polyunsaturated C18 fatty acids, α-linolenic acid (ALA, C18:3n-3) and stearidonic acid (C18:4n-3). The n-3-FA content is different to the trait n-3 LC-PUFA, which exclusively comprises n-3 FA with a chain length \> C18. As an essential FA, ALA cannot be synthesized by mammalian species and must be obtained from the diet. The ALA concentration in skeletal muscle, therefore, could be linked to the dietary absorption. However, the standardized concentrate-based feeding regimen in our study provides uniform feeding conditions for the animals. ALA is the precursor for the n-3 FA pathway \[[@B52]\] by serving as parent FA for the synthesis of stearidonic acid and n-3 LC-PUFA (EPA, DPA, and DHA) via sequential steps of desaturation and/or chain-elongation. The association of *ACSL1 c.481-233A\>G*with DPA and with n-3 LC-PUFA (containing n-3 FA exceeding a chain length of C18) could suggest that a substantial proportion of their precursor ALA might be activated and channeled to chain elongation processes.

The trait PUFA comprises both FA types, the n-6 and n-3 FA. The *ACSL1 c.481-233A\>G*variant showed no significant impact on n-6 FA content and thus, its association with PUFA could be due to its effect on the trait\'s component n-3 FA.

Interestingly, the *ACSL1*gene variant *c.481-233A\>G*that affected FA profiles in bovine skeletal muscle had no significant influence on the ratio n-6/n-3 FA in this tissue. Considering the standardized uniform feeding regimen in our study, this result could support the findings from other studies, which indicate that the n-6/n-3 FA ratio may be affected more by feeding than by genetics \[[@B53],[@B54]\]. In contrast, we found the *ACSL1*gene variant *c.481-233A\>G*to be associated with the LA/ALA (C18:2 n-6/C18:3 n-3) ratio. Furthermore, we observed significant associations of this gene variant with the ratios PUFA/SFA and P/S in our study, both representing characteristics of meat quality and widely used to evaluate the nutritional value of meat fat content. Again, the c.481-233A allele revealed an increasing effect on these ratios compared to the *c.481-233G*allele.

In contrast to the increasing effect associated with the *c.481-233A*allele on the relative content of the FA fractions, n-3 FA, PUFA, DPA, and n-3 LC-PUFA, and the PUFA/SFA and P/S ratios, we observed a decreasing effect of this allele on the absolute content of the trans vaccenic acid C18:1*trans-*11 in skeletal muscle in our study. This effect was in concert with the associated parallel decrease in total FA and MUFA content in the tissue. The effect on C18:1trans-11 is of particular interest, because trans vaccenic acid is a precursor of conjugated linoleic acid (CLAcis-9, trans-11) generation. CLAs are believed to have several important physiological functions, including anti-carcinogenic, anti-atherogenic, immunomodulating, growth and lean body mass promoting effects \[[@B55]\]. Thus, targeted selection of cattle carrying the homozygous *c.481-233A/c.481-233A*genotype in the *ACSL1*gene would possibly be accompanied by detrimental effects on the CLA profile in skeletal muscle.

There is the open question, whether the significant effects of the *ACSL1*gene variant *c.481-233A\>G*on FA composition were due to general fatness differences in skeletal muscle, which is supported by several QTL for marbling in the targeted chromosomal region, or whether the effects were associated with the *ACSL1*gene variant *c.481-233A\>G*. Alternatively, the effects of this gene variant might modulate the accumulation of specific FAs in skeletal muscle. To address this issue, we extended our association analysis and fitted IMF as a covariate in the model. When adjusting for IMF (Table [2](#T2){ref-type="table"}), the association of the *ACSL1*gene variant *c.481-233A\>G*with absolute content of trans vaccenic acid in skeletal muscle remained significant, whereas the other associations dropped below a stringent threshold of statistical significance (Bonferroni q \< 0.1) and were only tentatively significant (e.g., for relative content of n-3 FA and DPA). Thus, we cannot exclude that variants in the bovine *ACSL1*gene may exert a substantial effect on total intramuscular fat content, which indirectly affects intramuscular composition of specific FA fractions. However, as the results for trans vaccenic acid demonstrate, it is suggested that there are also direct effects associated with the *ACSL1*gene variant *c.481-233A\>G*on intramuscular content of specific FAs.

Conclusions
===========

Due to our observation that the *c.481-233A\>G*SNP in intron 5 of the *ACSL1*gene cannot fully explain the QTL variance (Figure [1](#F1){ref-type="fig"}), we conclude that this gene variant is presumably not causal, but in LD to another not yet detected polymorphism in its close vicinity affecting FA composition in bovine skeletal muscle. Presumably, these effects are not exclusively the consequence of variation in intramuscular fat content, but due to effects on specific FA. Prior to selective breeding of cattle carrying the desired genotype of the *ACSL1*gene variant *c.481-233A\>G*in order to produce meat with specific FA profiles, the association between *c.481-233A\>G*and FA composition has to be confirmed in the particular target cattle population.

Nevertheless, our results indicate that the *ACSL1*gene might play a functional role in mediating the FA composition in bovine skeletal muscle and provide a basis to further elucidate the function of the *ACSL1*gene and its coordinated network with genes integrated in FA metabolism to dissect the molecular background of lipid composition of beef.

Methods
=======

Animals and phenotypes
----------------------

The generation of the Charolais × German Holstein resource cross population (SEGFAM), details regarding feeding and housing of the animals analyzed in our study, have been previously described \[[@B43],[@B44]\]. The animals were kept under standardized environmental and feeding conditions in barn facilities at the Leibniz Institute for Farm Animal Biology (FBN). After birth, the calves were fed a milk/replacer/hay/concentrate diet *ad libitum*until day 121. Thereafter, the animals received a feed ration of concentrates and chaffed hay with a hay to concentrate ratio of 1:3 and an energy content of 12.7 MJ ME/kg dry matter fed *ad libitum*until slaughter. The animals were kept in a tight stall barn with individual daily feed recording. At the age of 18 months (547 days of age), the male animals were slaughtered, and a detailed dissection of the carcass was performed. A wide range of phenotypic data related to beef production and beef quality including FA composition were recorded including FA composition of selected skeletal muscles.

Analysis of FA composition of lipids involving 26 different FAs in skeletal muscle (*M. longissimus dorsi*) was determined for 156 F~2~bulls using capillary gas chromatography as described previously \[[@B56]\]. The absolute amount of FAs in skeletal muscle was determined from 2 g of skeletal muscle and calculated as mg/100 g tissue. The relative content of individual fatty acids was calculated as percentage of the total amount of FAs extracted. Based on the data obtained for individual fatty acids, sums of specific fatty acid fractions were calculated: saturated fatty acids (SFA), unsaturated fatty acids (UFA), monounsaturated fatty acids (MUFA), trans fatty acids (TFA), n-3 fatty acids (n-3 FA), n-6 fatty acids (n-6 FA), polyunsaturated fatty acids (PUFA) and n-3 long-chain PUFA (n-3 LC-PUFA). Furthermore, the ratios n-6/n-3 FA, MUFA/SFA, PUFA/SFA, P/S and LA/ALA as well as four different Δ^9^desaturase indices \[[@B57]\] were calculated. Intramuscular fat (IMF) content (percentage in 100 g tissue) was ascertained in *M. longissimus dorsi*by FoodScan Lab (FOSS) as described previously \[[@B56]\]. The phenotypic traits for FA composition of IMF included in our study are summarized in Table [3](#T3){ref-type="table"}.

###### 

Phenotypic traits characterizing fatty acid composition in skeletal muscle

  ------------------------------------------------------------------------------------------------------------------
  Trivial name                    Abbreviation             Mean of absolute\    SD        Mean of relative\   SD
                                                           content (mg/100 g)             content (%)         
  ------------------------------- ------------------------ -------------------- --------- ------------------- ------
  Lauric acid                     C12:0                    2.83\*               1.80      0.10                0.04

  Myristoleic acid                C14:1cis-9               18.53                17.85     0.62                0.31

  Myristic acid                   C14:0                    92.12\*              65.50     3.10\*              0.66

  Palmitoleic acid                C16:1cis-9               109.33\*             76.59     3.73                0.83

  Palmitic acid                   C16:0                    823.94\*             490.88    28.77               1.86

  Heptadecenoic acid              C17:1cis-10              23.48\*              12.51     0.85                0.18

  Margaric acid                   C17:0                    34.94\*              18.13     1.26\*              0.25

  Stearic acid                    C18:0                    373.40\*             199.95    4.96\*              1.80

  Oleic acid                      C18:1cis-9               981.37\*             578.52    34.35               2.60

  Vaccenic acid                   C18:1cis-11              43.60\*              30.60     13.41               1.65

  trans Vaccenic acid             C18:1trans-11            28.40\*              20.18     1.52\*              0.33

  Linoleic acid (LA)              C18:2n-6                 121.45\*             29.94     0.99\*              0.43

  Linolelaidic acid               C18:2trans-9, trans-12   4.11\*               3.39      0.11                0.13

  Conjugated linoleic acid        CLAcis-9, trans-11       5.99\*               4.73      0.20                0.09

  α-Linolenic acid (ALA)          C18:3n-3                 12.99                4.97      0.50\*              0.14

  Stearidonic acid (SDA)          C18:4n-3                 2.70                 3.36      0.15                0.10

  Arachidic acid                  C20:0                    2.94                 1.90      0.11                0.06

  Eisosenoic acid                 C20:1n-9                 4.21\*               2.80      0.35                0.15

  Eisosatrienoic acid (ETE)       C20:3n-3                 8.15\*               1.86      0.11\*              0.05

  Arachidonic acid (AA)           C20:4n-6                 33.89                7.60      1.48\*              0.74

  Timnodonic acid, EPA            C20:5n-3                 2.41\*               0.70      0.14\*              0.03

  Erucic acid                     C22:1n-9                 0.46\*               0.24      0.02\*              0.01

  Adrenic acid                    C22:4n-6                 6.20                 1.53      0.28                0.13

  Clupadonic acid, DPA            C22:5n-3                 6.51\*               1.34      0.26\*              0.11

  Cervonic acid, DHA              C22:6n-3                 0.92                 0.45      0.04                0.03

  Lignoceric acid                 C24:0                    0.82                 0.44      0.03\*              0.02

  ∑ Saturated fatty acids         SFA                      1352.06\*            777.93    47.55               2.38

  ∑ Unsaturated fatty acids       UFA                      1463.62\*            777.61    52.45               2.38

  ∑ Polyunsaturated fatty acids   PUFA                     208.34\*             44.62     8.57\*              3.02

  ∑ Monounsaturated fatty acids   MUFA                     1208.85\*            726.67    42.19\*             3.16

  ∑ trans fatty acids             TFA                      43.92\*              24.70     1.58                0.47

  ∑ n-3 fatty acids               n-3FA                    24.75                6.42      1.01\*              0.35

  ∑ n-3 long-chain PUFA           n-3 LCPUFA               9.58                 2.21      0.42\*              0.20

  ∑ n-6 fatty acids               n-6FA                    167.28\*             34.88     6.94                2.64

  ∑ n-6 long-chain PUFA           n-6 LCPUFA               40.09                8.62      1.78                0.85

  ∑ Total fatty acids             FA                       2743.81\*            1524.08                       

  Ratio n-6/n-3                   n-6/n-3                  6.96                 1.42                          

  Ratio MUFA/SFA                  MUFA/SFA                 0.89                 0.09                          

  Ratio PUFA/SFA                  PUFA/SFA                 0.18\*               0.07                          

  Ratio P/S                       P/S                      0.12\*               0.05                          

  Ratio C18:2n-6/C18:3n-3         LA/ALA                   9.86\*               2.51                          

  Δ^9^-desaturase index MUFA      Δ9MUFA                   46.39                2.56                          

  Δ^9^-desaturase index C14       Δ9C14                    16.31                6.65                          

  Δ^9^-desaturase index C16       Δ9C16                    11.40                2.08                          

  Δ^9^-desaturase index C18       Δ9C18                    72.16                3.34                          

  Intramuscular fat content       IMF                                                     2.56                1.13
  ------------------------------------------------------------------------------------------------------------------

SD: standard deviation

\*Data displaying distributions significantly different from normality (p \< 0.01) were log-transformed.

SFA = C12:0 + C14:0 + C16:0 + C17:0 + C18:0 + C20:0 + C24:0

MUFA = C14:1 + C16:1 + C17:1 + C18:1 + C20:1 + C22:1 + C18:1cis-9 + C18:1cis-11 + C18:1trans-11

UFA = MUFA + PUFA

Total FA = sum of all fatty acids determined

n-3FA = C18:3n-3 + C18:4n-3 + C20:3n-3 + C20:5n-3 + C22:5n-3 + C22:6n-3

n-6FA = C18:2n-6 + C18:3n-6 + C20:2n-6 + C20:3n-6 + C20:4n-6 + C22:2n-6 + C22:4n-6

PUFA = n-3FA + n-6FA

n-3 LC-PUFA = C20:3n-3 + C22:6n-3 + C22:5n-3 + C20:5n-3

TFA = C18:1trans-11 + C18:2trans-9, trans-12

LA/ALA = C18:2n-6/C18:3n-3

P/S = C18:2 n-6 + C18:3 n-3/C14:0 + C16:0 + C18:0

Δ^9^MUFA = \[(C14:1 + C16:1 + C17:1 + C18:1cis-9 + CLAcis-9, trans-11)/(C14:1 + C16:1 + C17:1 + C18:1cis-9 +

C18:1trans-11 + C14:0 + C16:0 + C17:0 + C18:0 + CLAcis-9, trans-11)\] × 100

Δ^9^C14 = \[C14:1/(C14:0 + C14:1)\] × 100

Δ^9^C16 = \[C16:1/(C16:0 + C16:1)\] × 100

Δ^9^C18 = \[(C18:1cis-9 + CLAcis-9, trans-11/(C18:0 + C18:1cis-9 + C18:1trans-11 + CLAcis-9, trans-11)\] × 100

QTL analysis
------------

An initial QTL scan comprising 244 microsatellite markers \[[@B58]\] for variation of FA composition in skeletal muscle had pinpointed a region on bovine chromosome 27 (BTA27) with effect on n-3 PUFA content in skeletal muscle. Five microsatellite markers located on BTA27 (*BM3507, RM209, BMS689, BM1857, BM203*) had been genotyped in all 733 P~0~, F~1~, and F~2~individuals of the Charolais × German Holstein resource population.

The respective QTL interval pointed to a chromosomal region on BTA27 harboring the *acyl-CoA synthetase long-chain family member 1*(*ACSL1*) gene according to the sequence assembly of the chromosome. Therefore, in a second step of our analysis, nine intragenic *ACSL1*SNPs (Figure [1](#F1){ref-type="fig"}) were added to the initial marker set. All microsatellite markers and all genotyped *ACSL1*SNPs were included to calculate a genetic map using CRIMAP Version 2.50 \[[@B59]\], incorporating modifications by Ian Evans and Jill Maddox (University of Melbourne). The resulting genetic map was applied in the QTL analyses with a variance component QTL model as implemented in Qxpak \[[@B60]\] and essentially as described previously \[[@B43]\]:

$$\textsf{y} = \mathbf{F}b + \mathbf{Z}u + \mathbf{Q}g + e;$$

where y is a vector of phenotypes, *b*is a vector of the fixed effects (slaughter year, *NCAPG I442M*genotype), *u*is the vector of individual infinitesimal polygenic effects, *g*is a vector of the additive QTL effects not fixed within founder breeds; **F**, **Z**and **Q**represent the incidence matrices for the fixed, polygenic and the QTL effect, respectively, and *e*is the vector of random residuals. An MCMC algorithm was used to calculate identity-by-descent probabilities as implemented in Qxpak. The *NCAPG I442M*mutation was included in the model, because previous analyses had shown a major effect of the mutation on carcass lipid deposition and growth in the resource population \[[@B44]\].

Statistical significance of the QTL analyses was tested by a likelihood-ratio test (LRT). Significance thresholds for the LRT were determined according to \[[@B61]\], considering one chromosome with a length of 0.6 M and an average marker density of 0.1 M. The significance thresholds for false positive results with α = 0.05 and α = 0.01 correspond to LRT values \> 7.2 and LRT \> 10.2, respectively.

Structural analysis of the ACSL1 gene
-------------------------------------

The coding sequence of the bovine *ACSL1*gene is represented by the reference mRNA sequence NM_001076085.1, which spans 3690 bp and is located on BTA27.

At the beginning of our study, the previous bovine genome assembly Btau4.0 and the current reference assembly Btau4.2 available at NCBI (<http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&PROG_DEF=blastn&BLAST_PROG_DEF=megaBlast&SHOW_DEFAULTS=on&BLAST_SPEC=OGP__9913__10708>, \[[@B62]\]) annotated the bovine *ACSL1*gene with a total of 19 protein-coding exons. *In silico*sequence analysis of the respective mRNA and protein sequences (NM_001076085.1 and NP_001069553) revealed that parts of the sequences could not be aligned to the bovine genome reference assembly Btau4.2. This indicated an incomplete annotation of the bovine *ACSL1*gene. However, in the alternative bovine genome assembly Bos_taurus_UMD3.1 (<ftp://ftp.cbcb.umd.edu/pub/data/assembly/Bos_taurus/Bos_taurus_UMD_3.1/>, \[[@B63]\]) integrated into the recent bovine genome assembly, Build 5.2, at NCBI (<http://www.ncbi.nlm.nih.gov/projects/mapview/map_search.cgi?taxid=9913>), the bovine *ACSL1*gene was annotated with a total of 21 protein-coding exons, which is also in agreement with the earlier bovine genome assembly, version Btau3.1. Comparative sequence analysis between gene and protein sequences of the bovine *ACSL1*gene and those of the orthologous human counterparts (NM_001995.2 and NP_001986.2) and the current human genome assembly Hsa37.2 (<http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&PROG_DEF=blastn&BLAST_PROG_DEF=megaBlast&SHOW_DEFAULTS=on&SHOW_DEFAULTS=on&BLAST_SPEC=OGP__9606__9558>) showed that the mRNA and amino acid sequences of both species display a high similarity (88% and 91% identity, respectively), which supported the annotation of the current Bos_taurus_UMD3.1 and the earlier Btau3.1 assemblies.

An experimental confirmation of the bovine *ACSL1*gene structure was required because of the inconsistent annotation of the ACSL1 gene. Therefore, fragments completely covering the coding region of the gene and the 5\' und 3\' UTRs, including the respective critical gene fragments with discordant structure annotation, were validated in our study. Exon-flanking primers (Table [4](#T4){ref-type="table"}) were derived from the sequence contigs NW_001494406.2 and NW_930554.1 and used for PCR-amplification with genomic DNA and cDNA. Genomic DNA was isolated from blood leucocytes using standard methods. The cDNA was prepared from liver tissue of a lactating cow. Total RNA extraction and cDNA synthesis by reverse transcription were performed as described recently \[[@B43]\]. To amplify cDNA fragments of the *ACSL1*gene, PCR was performed with cDNA using gene-fragment specific primers (Table [4](#T4){ref-type="table"}). The PCR-amplicons were isolated from agarose gels using the NucleoSpin^®^Extract II kit (Macherey & Nagel) and sequenced with PCR primers using BigDye^©^sequencing chemistry on a capillary sequencer (MEGABACE, GE Healthcare).

###### 

Primer sequences for the bovine ACSL1 gene applied for annotation confirmation, screening for polymorphisms and genotyping

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Primer           Sequence (5\' → 3\')        Gene region          Amplicon (bp)   Position in reference sequence   AccNo. of reference sequence   Application\*
  ---------------- --------------------------- -------------------- --------------- -------------------------------- ------------------------------ ------------------
  ACSL1_F1\        CCGAGCCCCAACCGAGAC\         intron 1 -promoter   844             1918181 - 1918198\               NW_001494406.2                 SNP
  ACSL1_R1         TGGACGCTGTTCTTGAGTGGTG                                           1919003 - 1919024                                               

  ACSL1_E1_F3\     GACCCGAGCCCCAACCGAG\        intron 1 -promoter   497             1918178 - 1918196\               NW_001494406.2                 SNP
  ACSL1_E1SF       GTTGAGCCACCACAATTTACTC                                           1918674 - 1918653                                               

  ACSL1_E1SR\      GGACTGCCCTGGATTTCACAAG\     promoter             413             1918612 - 1918633\               NW_001494406.2                 SNP
  ACSL1_R1         TGGACGCTGTTCTTGAGTGGTG                                           1919003 - 1919024                                               

  ACSL1_F2\        TCGCTGCTGAAGTCCTGTCTG\      exon 2               501             1897290 - 1897310\               NW_001494406.2                 SNP
  ACSL1_R2         GCTCTAATGCCCCCGTTGATG                                            1897770 - 1897790                                               

  ACSL1_F3\        TTGCGTGGGAGAGAGTTGTG\       exon 3               384             1882758 - 1882777\               NW_001494406.2                 SNP
  ACSL1_R3         TCAGGTGGAGGATTTATGTCAG                                           1883120 - 1883141                                               

  ACSL1_F4\        GCATCCACACTCCATAGAAAC\      exon 4               345             1881998 - 1882018\               NW_001494406.2                 SNP
  ACSL1_R4         AATAAAGAAGCAAAACTCAGACC                                          1882320 - 1882342                                               

  ACSL1_F5\        ATGAAAGGGAAAAGTGAAAGTG\     exon 5               457             1878288 - 1878309\               NW_001494406.2                 SNP
  ACSL1_R5         CTTGAGTTGGACCTGATGCTG                                            1878724 - 1878744                                               

  ACSL1_F6\        CGGCTGGAAGTAAAGAGACAC\      exon 6               574             1875840 - 1875860\               NW_001494406.2                 SNP
  ACSL1_R6         TTGTGTTCTTCATCCTCCTTTC                                           1876392 - 1876413                                               

  ACSL1_F7\        GTTCTCTTTTACAGGACCAG\       exon 7               600             1875542 - 1875561\               NW_001494406.2                 SNP
  ACSL1_R7         CAGGGATGCTTTACTTACTC                                             1876122 - 1876141                                               

  ACSL1_F8_9\      TGGGTGATGTAAATGTGTGAGG\     exons\               750             1872567 - 1872588\               NW_001494406.2                 SNP
  ACSL1_R8_9       ATGATAGGAATGGCAGTGGAGAC     8-9                                  1873294 - 1873316                                               

  ACSL1_F10\       ATCTGTATTTCAGGTACTGTTTC\    exon 10              287             1871656 - 1871678\               NW_001494406.2                 SNP
  ACSL1_R10        GTTTATGGGCTTCTCTCACG                                             1871923 - 1871942                                               

  ACSL1_F11\       TACACACTTGAACTTACCAG\       exon 11              314             1869171 - 1869190\               NW_001494406.2                 SNP
  ACSL1_R11        TGTGCTCTGAAATAAATGG                                              1869466 - 1869484                                               

  ACSL1_F12\       TCTGTATTGTGCCTTCTGATG\      exon 12              371             1866801 - 1866821\               NW_001494406.2                 SNP
  ACSL1_R12        GGAAACTGGGCTGAAATGC                                              1867153 - 1867171                                               

  ACSL1_F13\       TCTCACACAATAAAGGGGTAGG\     exon 13              516             1864669 - 1864690\               NW_001494406.2                 SNP
  ACSL1_R13        TCCACATCTTCACCAACACTC                                            1865164 - 1865184                                               

  ACSL1_F14\       AAGCCGCCCAGGAATAACAC\       exon 14              516             1863888 - 1863907\               NW_001494406.2                 SNP
  ACSL1_R14        TGCCACAAACCCACGACACT                                             1864384 - 1864403                                               

  ACSL1_F15\       GACTTGTGTTTATTTCTGCCTG\     exon 15              524             1862774 - 1862795\               NW_001494406.2                 SNP
  ACSL1_R15        TGGGCTGAGGTTTCTAATCC                                             1863278 - 1863297                                               

  ACSL1_F16\       TGCTGAGAAGTGGCTGGTTAC\      exon 16              247             1860135 - 1860155\               NW_001494406.2                 SNP
  ACSL1_R16        CATGAGAACAGGGCTTATTGG                                            1860361 - 1860381                                               

  ACSL1_F17\       ATGCGAGGGAGAAAGAGG\         exon 17              427             1859039 - 1859056\               NW_001494406.2                 SNP
  ACSL1_R17        CCGCTAACAAAAAGAACAGTG                                            1859445 - 1859465                                               

  ACSL1_F18\       GGCAAACTTCCCATTACACTG\      exon 18              512             1857386 - 1857406\               NW_001494406.2                 SNP
  ACSL1_R18        GACTCCTTCATCCCTTCTCTG                                            1857877 - 1857897                                               

  ACSL1_F19_20\    GCCAAAGCACACCACTCTC\        exons 19-20          517             139425 - 139443\                 NW_930554.1                    SNP
  ACSL1_R19_20     CGAAGCAGATAATAAGGAACTAC                                          139919 - 139941                                                 

  ACSL1_F21\       CACCCGCCTTTGTAACTG\         exon 21              548             138819 - 138836\                 NW_930554.1                    SNP
  ACSL1_R21        GTCCTGATTCTGTCCTGATGTC                                           139345 - 139366                                                 

  ACSL1_UTR_F31\   AAACCCTCTGGTCCTCTTGCG\      exon 21              404             138633 - 138653\                 NW_930554.1                    SNP
  ACSL1_UTR_R3     CAATGGCAGGAAGGGAGGGAG                                            139016 - 139036                                                 

  ACSL1_UTR_F2\    GAGTTTTCCAGATTCCTATGTCC\    exon 21              650             137966 - 137988\                 NW_930554.1                    SNP
  ACSL1_UTR_R21    CCTGTTACCCTCCCTTCCCTG                                            138595 - 138615                                                 

  ACSL1_UTR_F11\   ATGCGACTGCTGACATGAAAAAC\    exon 21              527             137530 - 137552\                 NW_930554.1                    SNP
  ACSL1_UTR_R1     AAATAAATGCTCTTCTGTCGTAATG                                        138032 - 138056                                                 

                                                                                                                                                    

  ACSL1_E1_F3\     GACCCGAGCCCCAACCGAG\        intron 1-promoter    220             1918178 - 1918196\               NW_001494406.2                 GT
  ACSL1_E1_R2      GCTCGTAGGCTGCAGCGAG                                              1918379 - 1918397                                               

  ACSL1_F7\        GTTCTCTTTTACAGGACCAG\       exon 7               600             1875542 - 1875561\               NW_001494406.2                 GT\
  ACSL1_R7         CAGGGATGCTTTACTTACTC                                             1876122 - 1876141                                               (PCR-RFLP)

  ACSL1_E1_F5\     GGAGGGAACTCGGGGAGCC\        promoter             451\            1918052 - 1918070\               NW_001494406.2                 GT\
  ACSL1_E1_R3\     AGGGCGGGGCTGAGACGG\                              316\            1918485 - 1918502\                                              (Tetra-ARMS PCR)
  ACSL1_E1_F7_T\   GCTATTTAAGGGTGCCGCCGT\                           175             1918328 - 1918348\                                              
  ACSL1_E1_R8_C    GCAGCCAGCTCTCGGAAGTAG                                            1918348 - 1918368                                               

                                                                                                                                                    

  ACSL1_E1_F2\     CGGAGGAGACTGTGGCTTAG\       exons\               505             38 - 58\                         NM_001076085.1                 cDNA
  ACSL1_E5_R1      CTGAGCGAAGATGCCAATAAAC      1-5                                  521 - 543                                                       

  ACSL1_E5_F1\     CAGTTTATTGGCATCTTCGCTC\     exons\               649             519 - 541\                       NM_001076085.1                 cDNA
  ACSL1_E12_R2     GGAAGATGGTGGGTTGAAGG        5-12                                 1148 - 1168                                                     

  ACSL1_E11_F2\    CCATATGTTTGAGAGAGTTGTAG\    exons 11-18          735             1046-1069\                       NM_001076085.1                 cDNA
  ACSL1_E18_R1     ATGTACTCCCCCTGTGCCAG                                             1761 - 1781                                                     

  ACSL1_E17_F2\    CTGGATAAAGACGGCTGGTTG\      exons 17-21          399             1665 - 1686\                     NM_001076085.1                 cDNA
  ACSL1_E21_R2     GAGTTCAGGGTGGAGATAGATG                                           2042 - 2064                                                     

  ACSL1_E21_R3     GTCAAACTCCCCTCCGCTTC        exons 17-21          540             2185 - 2205                      NM_001076085.1                 cDNA, RT

  ACSL1_E21_R4     CAGAAAGAGCAAAGTCCTAACC                                           2454 - 2476                      NM_001076085.1                 cDNA, RT
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* cDNA: analysis of cDNA structure, RT: reverse transcription, GT: genotyping, SNP: screening for polymorphisms

Screening for polymorphisms in the ACSL1 gene
---------------------------------------------

Screening for polymorphisms was carried out by re-sequencing and covered the complete coding sequence, exon-flanking intronic regions, the 5\' and 3\' UTRs and 724 bp of the promoter of the *ACSL1*gene. DNA primer pairs for PCR amplification and sequencing were designed based on genomic contig sequences (NW_001494406.2 and NW_930554.1) and the mRNA sequence (NM_001076085.1), respectively (Table [4](#T4){ref-type="table"}).

Four genomic DNA pools consisting of selected animals from the Charolais × Holstein resource population differing in their intramuscular fat content and index of delta 9-desaturase were established and subjected to screening for gene variants by comparative re-sequencing. The IMF pools contained DNA from sampling time- and pedigree-matched animals with high (n = 5, 4.93 ± 1.73%) and low (n = 7, 1.78 ± 0.21%) IMF. The Δ^9^desaturase index pools consisted of DNA from sampling time- and pedigree-matched animals with a high (n = 7; 50.87 ± 0.89) or low (n = 6, 43.86 ± 0.95) Δ^9^desaturase index. Furthermore, two genomic DNA samples from control individuals and two individual DNA samples originating from extreme animals displaying the lowest (1.63%) and highest (6.09%) IMF were included to validate the results received from the pools.

Genomic DNA was isolated from blood leucocytes using standard methods. PCR with exon-flanking primers (Table [4](#T4){ref-type="table"}) was performed with a total of 60 ng genomic DNA as described above. The generated PCR products were purified using the peqGOLD Cycle-Pure Kit (PEQLAB) according to the manufacturer\'s instructions and sequenced. Sequencing was performed on a capillary sequencer (MEGABACE, GE Healthcare) with primers used for targeted PCR amplification. To identify variable DNA positions, the sequences were analyzed meticulously by visual inspection of the sequencing profiles from DNA-pools and individuals\' DNA and by sequence alignment to the reference cDNA sequence (NM_001076085.1) as well as to the respective bovine genome sequences. All SNPs identified by sequencing of DNA pools were verified by single sample re-sequencing.

SNP Genotyping
--------------

Out of the identified 19 *ACSL1*SNPs (see Table [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}), nine were genotyped in the Charolais × German Holstein resource population: Two exonic SNPs (*c.516C\>G, c.1938T\>G*) and five intronic SNPs (*c.481-233A\>G, c.580+114C\>G, c.845-58T\>G, c.1267-100C\>T, c.1959+56G\>A*) were genotyped on an Illumina Beadstation \[[@B64]\] as part of a targeted 384 SNP GoldenGate assay. The SNP in exon 7 (*c.584A\>G*) was analyzed using a PCR-RFLP assay with primers for amplification of the targeted region (Table [4](#T4){ref-type="table"}) and the restriction enzyme *SacI*(Fermentas). The promoter SNP *c.-122G\>A*was genotyped by a Tetra-ARMS PCR assay \[[@B65]\] and validated by direct sequencing. The respective primers are given in Table [4](#T4){ref-type="table"}. The *NCAPG I442M*mutation was genotyped by PCR-RFLP \[[@B43]\].

Association analysis
--------------------

Prior to association analysis, we tested whether the phenotypic data of the individual traits were normally distributed using the Shapiro Wilk test. For those data displaying distributions significantly different from normality (P \< 0.01), we performed natural log (ln) transformation, and the log- transformed data were subjected to association analysis. The respective data are indicated in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.

The BTA27 marker haplotypes of the individuals of the resource population were estimated by a Markov chain Monte Carlo (MCMC) algorithm implemented in Qxpak \[[@B60]\]. The corresponding haplotypes were submitted to pairwise LD analysis calculating r^2^values using PowerMarker V3.25 \[[@B66]\].

Subsequently to the QTL analyses, association analyses were performed between ACSL1 gene SNPs and the absolute and relative FA composition traits in *M. longissimus dorsi*. The following model testing for LD as implemented in Qxpak \[[@B60]\] was applied:

$$y_{i} = a_{p} + \sum\limits_{k}\sum\limits_{h}\lambda_{ikh}g_{k} + \sum\limits_{m}\sum\limits_{n}\lambda_{imn}g_{m} + u_{i} + e_{ihkmnp}$$

where y~i~is the record of individual i, a~p~is the fixed effect of slaughter year p, λ~ihk~is an indicator variable for the *NCAPG I442M*locus, which is 1 when the allele at the h^th^haplotype (1 or 2) of the i^th^individual is 1 and otherwise 0, λ~imn~is a respective indicator variable for the specific *ACSL1*SNP, u~i~is the infinitesimal genetic effect of individual i, g~k~and g~m~are the respective allelic effects for *NCAPG I442M*and the *ACSL1*SNP, and e~ihkmnp~is the residual. Analogous to the QTL analyses, the *NCAPG I442M*mutation was included in the model, because previous analyses had shown a major effect of the mutation on carcass lipid deposition and growth in the resource population \[[@B44]\]. A likelihood-ratio test (likelihood of model with both loci vs. likelihood of model with *NCAPG I442M*) was applied to test for statistical significance. In order to dissect whether the association of the respective *ACSL1*variant with intramuscular FA composition is solely due to indirect effects on IMF or a consequence of direct effects on the specific FA accumulation, we extended the model and fitted IMF as an additional covariate. A Bonferroni correction was calculated (q-value) to account for testing several SNPs in order to avoid false positive associations. The q-values thresholds of 0.05 and 0.1, respectively, indicate an experiment-wise significant or suggestive association, respectively. Finally, an additive fixed effect of the SNP in intron 5 was added in the QTL model described above to test whether this SNP might explain the QTL variance at the identified position on BTA27.
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